Post by partimefriend on Jan 17, 2020 21:53:51 GMT -5
3 Epic Health Breakthroughs from 2019
Discover three of the ways Johnson & Johnson made a positive impact on the health of people everywhere in 2019—and find out how you can join our team today.
www.careers.jnj.com/careers/3-epic-health-breakthroughs-from-2019
The impact of the hepatitis B virus (HBV) on human health is almost impossible to overstate. Take the following stats from the World Health Organization (WHO), for example:
Around 257 million people worldwide are chronically infected with HBV.
HBV is directly responsible for more than 800,000 deaths annually.
The disease is believed to cause approximately 40% of all primary liver cancers, which is the world's second-deadliest cancer.
But the WHO also notes that HBV research has been "drastically underfunded" in recent years. We're working to change that by focusing on what's called a "functional cure": a cure that brings HBV markers to undetectable levels in the blood, even after treatment has been stopped. And we've already made some important headway.
Most notably, this past August the Janssen Pharmaceutical Companies of Johnson & Johnson began dosing in a Phase 2b study (REEF-1) of different combination regimens for the treatment of chronic HBV infection. It's our first-ever triple-combination hepatitis B study to be tested in Phase 2b of clinical development.
Stay tuned! We certainly hope to have more progress to report soon!
Discover three of the ways Johnson & Johnson made a positive impact on the health of people everywhere in 2019—and find out how you can join our team today.
www.careers.jnj.com/careers/3-epic-health-breakthroughs-from-2019
The impact of the hepatitis B virus (HBV) on human health is almost impossible to overstate. Take the following stats from the World Health Organization (WHO), for example:
Around 257 million people worldwide are chronically infected with HBV.
HBV is directly responsible for more than 800,000 deaths annually.
The disease is believed to cause approximately 40% of all primary liver cancers, which is the world's second-deadliest cancer.
But the WHO also notes that HBV research has been "drastically underfunded" in recent years. We're working to change that by focusing on what's called a "functional cure": a cure that brings HBV markers to undetectable levels in the blood, even after treatment has been stopped. And we've already made some important headway.
Most notably, this past August the Janssen Pharmaceutical Companies of Johnson & Johnson began dosing in a Phase 2b study (REEF-1) of different combination regimens for the treatment of chronic HBV infection. It's our first-ever triple-combination hepatitis B study to be tested in Phase 2b of clinical development.
Stay tuned! We certainly hope to have more progress to report soon!